ROSTOCK, Germany--(BUSINESS WIRE)--CENTOGENE today announced that it will be hosting a two day rare disease event at its headquarters in Rostock, Germany. The event, to be held on February 20-21 2019, ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 10, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world ...

ROSTOCK, Germany--(BUSINESS WIRE)--CENTOGENE, the worldwide leader in using genetic and proteomic knowledge to enable patients, clinicians and pharmaceutical partners to identify and accelerate ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (CNTGF), the essential life science partner for data-driven answers in rare and neurodegenerative ...

Testing of airport employees, who will be in contact with passengers as part of the forthcoming flight on Saturday, results were available the same evening With its innovative scalable methods, ...

Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, ...

Nine ROPAD participants (0.3% of the cohort) were heterozygous for the RAB32 c.213C>G mutation, supporting the mutation's causal role in Parkinson’s disease Age at onset in mutation-positives and ...